6.40Open6.40Pre Close0 Volume1 Open Interest55.00Strike Price0.00Turnover35.18%IV-1.25%PremiumDec 20, 2024Expiry Date7.00Intrinsic Value100Multiplier30DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9127Delta0.0429Gamma6.76Leverage Ratio-0.0092Theta-0.0204Rho-6.17Eff Leverage0.0212Vega
Sanofi Stock Discussion
$Heron Therapeutics (HRTX.US)$ : 🤔
⇨ ZYNRELEF® Vial Access Needle
‣ Postoperative pain
‣ PDUFA: 9/23/24 (sNDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ KarXT (xanomeline-trospium)
‣ Schizophrenia
‣ PDUFA: 9/26/24 (NDA)
$Sanofi (SNY.US)$ $Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Dupixent
‣ Chronic obstructive pulmonary disease
‣ PDUFA: 9/27/24 (sBLA)
$BeiGene (BGNE.US)$ $Merck & Co (MRK.US)$ & $Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Tislelizumab, KEYTRUDA, OPDIVO & YER...
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
The stock recently closed at $113.65, with a consensus price target of $117.74, indicating a potential upside of 3.60%.
Sanofi's market cap stands at $141.1 billion, with a P/E ratio of 30.47.
$Sanofi (SNY.US)$
$Travere Therapeutic (TVTX.US)$ : FILSPARI (Sparsentan)
$Avadel Pharmaceuticals (AVDL.US)$ : LUMRYZ (FT218)
$Iterum Therapeutics (ITRM.US)$ : Sulopenem - AdCom 🗓️
$Sanofi (SNY.US)$ & $Regeneron Pharmaceuticals (REGN.US)$ : Dupixent
$Vanda Pharmaceuticals (VNDA.US)$ : Tradipitant
$Zevra Therapeutics (ZVRA.US)$ : Arimoclomol
$Heron Therapeutics (HRTX.US)$ : ZYNRELEF® Vial Access Needle
$Merck & Co (MRK.US)$ : KEYTRUDA+ chemotherapy
$Bristol-Myers Squibb (BMY.US)$ : KarXT (...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
As reported by Forbes. The Novavax updated vaccine is much superior to the the moderna and Pfizer. It creates 48x antibodies while Moderna and Pfizer created 7x or 8x only.
Why? The answer is imprinting. Once you get a shot of Wuhan mRNA vaccine the body remembers it and will always produce antibodies agai...
"We’re all in on AI. We want to become the first biopharma company powered by AI at scale" -
"We invest in AI that makes a difference for our people, patients, and partners" - #sanofi
Novavax
- 2021 Gets $1.6 billion government grant to develop its COVID shot
- Stock soars over $280
- 2024 - Sanofi is taking a 4.9% equity position in Novavax with 1.2 billion dollar deal with $500 Million up front.
- Malaria WHO Approved & rolled...
The Paris Olympics have signed on 79 sponsors, including 15 Global Partners like $Anheuser-Busch Inbev (BUD.US)$, ...
No comment yet